CONFERENCE DAY ONE
SEPTEMBER 9, 2025
PART ONE: FIND YOUR FUTURE PARTNER
Bringing you a targeted and scientifically aligned partnership opportunity from the start, this opening section brings key buyers
together in a unique and unmissable format to find your next partner and route to more capital.
8.00-8:45: Insights into pharma’s outlook for ADC deal-making with the pharma icebreaker panel
9.00-10.30: Introductions & Protected Networking: Qualify connections, hear feedback and generate interest for follow-up meetings at the pharma icebreaker roundtables
11.15-12.15: Where will Investors Invest? Understand what will drive or inhibit investor interest in ADC technologies
12.15-12.45: Connect with Investors: Swap business cards and find your company’s fit with investors during the investor icebreaker speed networking
7:50 am Session Chair’s Opening Remarks
Strategic Priorities & Opinions on New Innovations for Future Partnerships in ADC
8:00 am Pharma Icebreaker: Moderated Discussion Revealing Insights into Pharma’s Wish List & Successful Deal Structure
8:45 am Short Comfort Break Ahead of Networking Session
For Business Development & Networking: Follow up with Pharma
9:00 am Unlocking Unmatched Meetings:
Synopsis
- The Icebreaker Tables guarantee face-time for biotech to sit at tables with pharma from the panel before.
- Once meetings schedules form on the One-on-One Partnering Portal, pharma pick biotech of interest and biotech select pharma not yet on their meeting calendar. From this, we create a schedule for biotech to rotate through match-making tables. Break the ice, ask questions to assess alignment and initiate interest for follow up with key contacts who are on your hit-list but not yet on your One-on-One Partnering schedule.
For Scientific Insights & Discussion: Assessing Future Research Trends
9:00 am The Calm Before the Storm: Navigating a Tidal Wave of ADCs
9:30 am ADCs x Radioligands: The Use of One Technology to Advance the Other
Synopsis
- Discussing key learnings for both technologies to understand where they can lend value to each other
- Convergence of targeting technologies between ADCs and Radio
- Using linker technology from ADC to improve the rapid uptake and excretion profile of radioligands when separating target ligands from radioligand payloads in the tumor
- Overcoming challenges associated with elimination, how do you get an ADC out of the body?
10:00 am Advanced Patent Considerations for ADCs & Conjugates
Synopsis
- Analyzing the ADC IP and competitive landscape and trends
- Discussing key patentability issues for ADCs and conjugates
- Providing strategic approaches for protecting novel ADCs and conjugates and freedom to operate
10:30 am Morning Break & One-on-One Meeting Schedule Opens
11:45 am Investor Icebreaker: When Being Selective, where will Investors Invest?
Synopsis
- For both venture and investing out of public funds, what will drive investment in ADCs and what will inhibit it?
- With the data readouts from ASCO, will your considerations for investment change?
- How can and will ADCs remain relevant to investors?
12:15 pm Investors Icebreaker: Speed Networking
Synopsis
Straight after the Investor Icebreaker, join high tables in small groups with an investor at each table. For rounds of five minutes, biotech stays at tables and investors move around. Rapidly gauge alignment between portfolios and stage of the company, share business cards, or ask a follow-up question from the panel before the investors rotate and a new
round begins.
12:45 pm Lunch Break & Networking
2:30 pm One-on-One Meeting Schedule Pauses for Presentations to Start
PART TWO: SHOWCASE YOUR SCIENCE
Designed to foster excitement and engagement in innovative companies, be part of back-to-back presentations to showcase
your pipeline, platform, and technologies to a room of aligned and qualified decision-makers.
Novel Payloads & Linker Conjugation
Synopsis
Demonstrating Value versus Risk, to Diversify & Invest in Novel Payload & Advanced Linker Conjugation Technologies
2:40 pm Session Chair’s Opening Remarks
Synopsis
- Novel Payloads as the New Value Driver for ADCs
- Why are new payloads needed?
- What new payloads are on the horizon?
- Case Study: Focusing on Iksuda’s novel protein alkylator (ProAlk) payload
3:00 pm Delivering a New Generation of Antibody-Drug Conjugates & Antibody Cancer Therapeutics
Synopsis
- Advancing clinical stage assets against validated cancer targets and promising preclinical pipeline
- Delivering diversity, selectivity and novel mechanisms of action
- Leveraging unique fully integrated, in-house discovery, development and manufacturing
3:20 pm Micvotabart Pelidotin (MICVO) – An Innovative Extracellular-Targeting ADC Rapidly Through Clinical Developement
Synopsis
- An extracellular ADC intentionally designed against a novel and specifically expressed noncellular cancer target, EDB+FN
- Ph1 Clinical data demonstrate PoC for MICVO's novel extracellular mechanism with favorable safety, PK, tolerability and early efficacy profile
- Initial development focus in R/M HNSCC with expansion potential into multiple solid tumors
3:40 pm Pre-Targeting with in Vivo Click Chemistry for Next-Gen ADCs & Radiopharmaceutical Therapies (RTPs)
Synopsis
- Mechanisms of dose-limiting, off-target toxicities associated with ADCs
- Pre-targeting as a solution to overcome off-target toxicities and deliver more payload to the tumor – or all payloads classes
- Using in vivo click chemistry as a reunion technology and how this can be used to improve efficacy by minimizing exposure to the body and maximizing tumor drug considerations
4:00 pm Novel & Dual Payloads: Assessing Linker Conjugation Technologies That Encourage Flexibility in Payloads
Synopsis
- Evaluating the right ratios, the advantages of releasing drugs in specific ratios, and which combination of drugs make sense when considering dual payloads
- Discussing how novel payloads hold promise to overcome drug resistance
- Advancing cytoxic or immune-stimulating payloads with novel MoAs
Afternoon Drinks Reception & Networking
4.00: ““People work with people”. Enjoy an informal networking drinks reception with all attending colleagues to catch up, candidly network, initiate and nurture business relationships built before or during the conference so far.
4.00 - 6.00: One-on-One Meeting Schedule Re-Opens
Available from 4.00 to 6.00 make the most of catching contacts away from the office and capitalize on meeting space adjacent to the networking drinks reception.